Working… Menu

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (THINKER-NEXT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04075916
Recruitment Status : Not yet recruiting
First Posted : September 2, 2019
Last Update Posted : September 2, 2019
Gilead Sciences
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
The Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER-NEXT] study will include adult kidney transplant candidates without hepatitis C virus (HCV) infection on the transplant waiting list who will consent to kidney transplantation from a deceased donor infected with HCV, followed by treatment with a direct acting antiviral. The one-year allograft function and one-year risk of CMV infection will be compared between THINKER-NEXT kidney transplant recipients and matched recipients who received hepatitis C uninfected kidney transplants (these patients are called Transplant Cohort). The mortality rate of kidney transplant candidates who enroll in THINKER-NEXT and consent to offers of kidneys from HCV-infected donors will be compared to matched wait-listed patients who do not consent to receive HCV-infected kidneys (these patients are called Wait-list Cohort). Lastly, renal pathologic findings will be compared among HCV-viremic donors and HCV-negative comparator donors.

Condition or disease Intervention/treatment Phase
End Stage Renal Disease Drug: Epclusa Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Estimated Study Start Date : November 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Epclusa (sofosbuvir/velpatasvir)
Epclusa is taken by mouth for 12 weeks as per the FDA label.
Drug: Epclusa
All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.

Primary Outcome Measures :
  1. Post-treatment sustained virologic response (SVR) to direct-acting antiviral (DAA) [ Time Frame: Baseline to 24 weeks ]
    The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR-12; negative HCV RNA 12 weeks after completing Epclusa therapy)/(number of subjects treated with Epclusa post-kidney transplantation)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to provide informed consent
  • Active waiting list status for isolated kidney transplant
  • 18 to 70 years of age
  • No living kidney donor
  • Panel reactive antibody ≤97%
  • Agreement for participation from patient's transplant nephrologist

Exclusion Criteria:

  • Hepatocellular carcinoma
  • Hepatitis B surface antigen and/or DNA positive
  • HCV nucleic acid test (NAT) positive (an isolated positive HCV Ab is not an exclusion)
  • Other chronic liver disease (excluding non-alcoholic fatty liver disease [NAFLD] with normal liver enzymes)
  • Persistently elevated liver transaminases (defined as the upper limit of normal at the reference laboratory)
  • Significant hepatic fibrosis on screening elastography (Fibroscan value ≥8kPa; equates to >F2 fibrosis on the Metavir staging system
  • Primary Focal Segmental Glomerulosclerosis (FSGS), FSGS recurring in initial transplant, or other disease process at high risk of early graft failure per the treating transplant
  • Current use of amiodarone (due to interaction with sofosbuvir)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04075916

Layout table for location contacts
Contact: Peter Reese, MD, MSCE (307) 22-THINK
Contact: Stacey Prenner, MD (307) 22-THINK

Layout table for location information
United States, Florida
Jackson Memorial Hospital/University of Miami Not yet recruiting
Miami, Florida, United States, 33136
Contact: David Goldberg, MD, MSCE   
Contact: Javier Pagan, MD   
Principal Investigator: David Goldberg, MD, MSCE         
United States, Maryland
Johns Hopkins Not yet recruiting
Baltimore, Maryland, United States, 21287
Contact: Christine Durand, MD   
Contact: Dorry Segev, MD, PhD   
Principal Investigator: Christine Durand, MD         
United States, Massachusetts
Massachusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Raymond Chung, MD   
Contact: Meghan Sise, MD   
Principal Investigator: Raymond Chung, MD         
United States, Missouri
Washington University in St. Louis Not yet recruiting
Saint Louis, Missouri, United States, 63110
Contact: William Chapman, MD, FACS   
Principal Investigator: William Chapman, MD, FACS         
United States, New York
New York Presbyterian Hospital/Columbia University Not yet recruiting
New York, New York, United States, 10032
Contact: Elizabeth Verna, MD   
Contact: Sumit Mohan, MD   
Principal Investigator: Elizabeth Verna, MD         
United States, Ohio
University of Cincinnati Not yet recruiting
Cincinnati, Ohio, United States, 45267
Contact: Steve Woodle, MD   
Principal Investigator: Steve Woodle, MD         
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Vanderbilt University Not yet recruiting
Nashville, Tennessee, United States, 37235
Contact: David Shaffer, MD, FACS   
Contact: Rachel Forbes, MD, MBA   
Principal Investigator: David Shaffer, MD, FACS         
Sponsors and Collaborators
University of Pennsylvania
Gilead Sciences
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Layout table for additonal information
Responsible Party: University of Pennsylvania Identifier: NCT04075916     History of Changes
Other Study ID Numbers: 10067385
First Posted: September 2, 2019    Key Record Dates
Last Update Posted: September 2, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Liver Diseases
Digestive System Diseases
Virus Diseases
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Hepatitis C
Hepatitis, Viral, Human
RNA Virus Infections
Flaviviridae Infections
Sofosbuvir-velpatasvir drug combination
Antiviral Agents
Anti-Infective Agents